Loading...

Deutsche Biotech Innovativ

DB:VUA
Snowflake Description

Mediocre balance sheet with weak fundamentals.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
VUA
DB
€64M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Deutsche Biotech Innovativ AG operates as a biotechnology company in Germany. The last earnings update was 212 days ago. More info.


Add to Portfolio Compare Print
VUA Share Price and Events
7 Day Returns
0%
DB:VUA
-2.4%
DE Biotechs
1.8%
DE Market
1 Year Returns
-0.7%
DB:VUA
-10.2%
DE Biotechs
-6%
DE Market
VUA Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Deutsche Biotech Innovativ (VUA) 0% 4.4% - -0.7% - -
DE Biotechs -2.4% 3.2% -7.7% -10.2% 51.2% 10.1%
DE Market 1.8% 4.6% 7.4% -6% 10.1% 15.3%
1 Year Return vs Industry and Market
  • VUA outperformed the Biotechs industry which returned -10.2% over the past year.
  • VUA outperformed the Market in Germany which returned -6% over the past year.
Price Volatility
VUA
Industry
5yr Volatility vs Market

VUA Value

 Is Deutsche Biotech Innovativ undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Deutsche Biotech Innovativ. This is due to cash flow or dividend data being unavailable. The share price is €70.5.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Deutsche Biotech Innovativ's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Deutsche Biotech Innovativ's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:VUA PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-06-30) in EUR €-0.25
DUSE:VUA Share Price ** DUSE (2019-04-03) in EUR €68
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 22.44x
Germany Market PE Ratio Median Figure of 424 Publicly-Listed Companies 19.59x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Deutsche Biotech Innovativ.

DB:VUA PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= DUSE:VUA Share Price ÷ EPS (both in EUR)

= 68 ÷ -0.25

-273.43x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Deutsche Biotech Innovativ is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Deutsche Biotech Innovativ is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Deutsche Biotech Innovativ's expected growth come at a high price?
Raw Data
DB:VUA PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -273.43x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.3x
Germany Market PEG Ratio Median Figure of 270 Publicly-Listed Companies 1.56x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Deutsche Biotech Innovativ, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Deutsche Biotech Innovativ's assets?
Raw Data
DB:VUA PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-06-30) in EUR €2.12
DUSE:VUA Share Price * DUSE (2019-04-03) in EUR €68
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.71x
Germany Market PB Ratio Median Figure of 574 Publicly-Listed Companies 1.84x
DB:VUA PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= DUSE:VUA Share Price ÷ Book Value per Share (both in EUR)

= 68 ÷ 2.12

32x

* Primary Listing of Deutsche Biotech Innovativ.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Deutsche Biotech Innovativ is overvalued based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Deutsche Biotech Innovativ's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Deutsche Biotech Innovativ has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

VUA Future Performance

 How is Deutsche Biotech Innovativ expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Deutsche Biotech Innovativ has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
47.5%
Expected Biotechs industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Deutsche Biotech Innovativ expected to grow at an attractive rate?
  • Unable to compare Deutsche Biotech Innovativ's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare Deutsche Biotech Innovativ's earnings growth to the Germany market average as no estimate data is available.
  • Unable to compare Deutsche Biotech Innovativ's revenue growth to the Germany market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
DB:VUA Future Growth Rates Data Sources
Data Point Source Value (per year)
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.5%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.6%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:VUA Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (9 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in EUR Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:VUA Past Financials Data
Date (Data in EUR Millions) Revenue Cash Flow Net Income *
2018-06-30 0 0 0
2018-03-31 0 0 0
2017-12-31 0 0 0
2017-09-30 0 0
2017-06-30 0 0 0
2017-03-31 0 0 0
2016-12-31 0 0 0
2016-09-30 0 0
2016-06-30 0 -1 0
2016-03-31 0 -1 -1
2015-12-31 0 -1 -1
2015-09-30 0 0 0

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if Deutsche Biotech Innovativ is high growth as no earnings estimate data is available.
  • Unable to determine if Deutsche Biotech Innovativ is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:VUA Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (9 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from Deutsche Biotech Innovativ Company Filings, last reported 9 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:VUA Past Financials Data
Date (Data in EUR Millions) EPS *
2018-06-30 -0.25
2018-03-31 -0.26
2017-12-31 -0.27
2017-09-30 -0.28
2017-06-30
2017-03-31
2016-12-31 -0.28
2016-09-30 -0.37
2016-06-30 -0.47
2016-03-31 -0.55
2015-12-31 -0.63
2015-09-30 -0.49

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Deutsche Biotech Innovativ will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Deutsche Biotech Innovativ's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Pharmaceuticals & Biotech companies here
  2. Deutsche Biotech Innovativ's competitive advantages and company strategy can generally be found in its financial reports archived here.
  3. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess Deutsche Biotech Innovativ's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Deutsche Biotech Innovativ has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

VUA Past Performance

  How has Deutsche Biotech Innovativ performed over the past 5 years?

  • Deutsche Biotech Innovativ's last earnings update was 212 days ago.
The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Deutsche Biotech Innovativ's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Deutsche Biotech Innovativ does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Deutsche Biotech Innovativ's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Deutsche Biotech Innovativ's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Deutsche Biotech Innovativ's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Deutsche Biotech Innovativ Company Filings, last reported 9 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:VUA Past Revenue, Cash Flow and Net Income Data
Date (Data in EUR Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-06-30 0.15 -0.24 0.22
2018-03-31 0.18 -0.24 0.24
2017-12-31 0.22 -0.25 0.26
2017-09-30 0.24 -0.26 0.26
2017-06-30 0.25 -0.27 0.26
2017-03-31 0.23 -0.27 0.24
2016-12-31 0.20 -0.26 0.23
2016-09-30 0.20 -0.35 0.21
2016-06-30 0.20 -0.44 0.19
2016-03-31 0.20 -0.52 0.19
2015-12-31 0.20 -0.60 0.20
2015-09-30 0.19 -0.46 0.21
2015-06-30 0.19 -0.32 0.21
2015-03-31 0.14 -0.23 0.16
2014-12-31 0.10 -0.15 0.10
2013-12-31 -0.09 0.01
2012-12-31 -0.15 0.02
2012-09-30 -0.14 0.02
2012-06-30 -0.13 0.02

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Deutsche Biotech Innovativ has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Deutsche Biotech Innovativ has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Deutsche Biotech Innovativ improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Deutsche Biotech Innovativ's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Deutsche Biotech Innovativ has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

VUA Health

 How is Deutsche Biotech Innovativ's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Deutsche Biotech Innovativ's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Deutsche Biotech Innovativ's short term (1 year) commitments are greater than its holdings of cash and other short term assets.
  • Deutsche Biotech Innovativ's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Deutsche Biotech Innovativ's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Deutsche Biotech Innovativ has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Deutsche Biotech Innovativ Company Filings, last reported 9 months ago.

DB:VUA Past Debt and Equity Data
Date (Data in EUR Millions) Total Equity Total Debt Cash & Short Term Investments
2018-06-30 2.01 0.00 0.06
2018-03-31 2.01 0.00 0.06
2017-12-31 2.10 0.00 0.14
2017-09-30 2.10 0.00 0.14
2017-06-30 2.10 0.00 0.14
2017-03-31 2.10 0.00 0.14
2016-12-31 2.20 0.00 0.23
2016-09-30 2.20 0.00 0.23
2016-06-30 2.37 0.00 0.34
2016-03-31 2.37 0.00 0.34
2015-12-31 2.46 0.30 1.52
2015-09-30 2.46 0.30 1.52
2015-06-30 1.17 0.00 0.09
2015-03-31 1.17 0.00 0.09
2014-12-31 1.42 0.00 0.48
2013-12-31 1.16 0.00 0.15
2012-12-31 0.94 0.00 0.18
2012-09-30 0.94 0.20 0.18
2012-06-30 1.02 0.00 0.03
  • Deutsche Biotech Innovativ has no debt.
  • Deutsche Biotech Innovativ had no debt 5 years ago.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Deutsche Biotech Innovativ has less than a year of cash runway based on current free cash flow.
  • Deutsche Biotech Innovativ has less than a year of cash runway if free cash flow continues to reduce at historical rates of -35.8% each year.
X
Financial health checks
We assess Deutsche Biotech Innovativ's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Deutsche Biotech Innovativ has a total score of 3/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

VUA Dividends

 What is Deutsche Biotech Innovativ's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Deutsche Biotech Innovativ dividends.
If you bought €2,000 of Deutsche Biotech Innovativ shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Deutsche Biotech Innovativ's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Deutsche Biotech Innovativ's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:VUA Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 327 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Deutsche Biotech Innovativ has not reported any payouts.
  • Unable to verify if Deutsche Biotech Innovativ's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Deutsche Biotech Innovativ's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Deutsche Biotech Innovativ has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Deutsche Biotech Innovativ's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Deutsche Biotech Innovativ afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Deutsche Biotech Innovativ has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

VUA Management

 What is the CEO of Deutsche Biotech Innovativ's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Bernd Wegener
AGE 71
CEO Bio

Mr. Bernd Wegener, FRICS, serves as the Chief Executive Officer at Adrenomed AG SM. Mr. Wegener served as the Chairman of Management Board and Chief Executive Officer at Deutsche Biotech Innovativ AG and serves as its Member of Management Board. Mr. Wegener serves as a Member of the Administrative Board of BPI-Service GmbH. He served as Managing Director of Deutsche Biotech Innovativ AG. Mr. Wegener served as Executive Board member of the Federal Association of the Pharmaceutical Industry from 2000 to 2014. In the year 1994, he led a management buyout of the diagnostics division of Henning Berlin and established BRAHMS Diagnostik, which he headed up as Managing Director. Mr. Wegener served as the Chief Executive Officer at BoRoAoHoMoS GmbH (alternate name Brahms AG) until January 31, 2006. He served as the Chairman and Member of Executive Board of B·R·A·H·M·S GmbH in 1994. The following years, Mr. Wegener developed BRAHMS to an international player in the field of in vitro diagnostics. In 1992, he served as the Managing Director and Chief Executive Officer at Henning Berlin GmbH. In 1984, Mr. Wegener became the Chief Executive Officer at Marion Merrell Dow GmbH. In 1981, he moved to Degussa Pharma Group where he served as the Sales Manager for Germany and Head of International Product Management until 1984. From 1974 to 1981, Mr. Wegener worked for Boehringer Ingelheim KG, becoming responsible for the German sales representatives. Mr. Wegener has been Chairman of the Federation of Pharmaceutical Industries since 2000. He served as the Chairman of Supervisory Board for WCG AG and co.don AG until December 1, 2017. Mr. Wegener served as the Chairman of the Board at BRAHMS AG from April 1, 2004 to January 31, 2006; Vice Chairman from November 20, 2003 to March 31, 2004; and a Director from July 2, 2003 to November 20, 2003. He served as the Chairman of the Supervisory Board at co.don AG from April 1, 2004 to January 2006 and serves as its Member of Supervisory Board. He serves as a Director of Adrenomed AG. He serves as a Member of Advisory Board at Peppermint VenturePartners GmbH. He also serves as a Member of the Advisory Board of IMS. He has been a Member of Supervisory Board at Deutsche Immobilien Chancen AG & Co. KGaA. Mr. Wegener served as a Member of the Supervisory Board of DIC Asset AG from February 15, 2005 to July 2015. He has been actively involved as an investor and a member of the supervisory bodies in several established companies, as well as numerous start-ups in the healthcare field. Besides his professional activities, Mr. Wegener volunteers in various public and non-profit organizations. He studied Veterinary Medicine at the University of Giessen.

CEO Compensation
  • Insufficient data for Bernd to compare compensation growth.
  • Insufficient data for Bernd to establish whether their remuneration is reasonable compared to companies of similar size in Germany.
Management Team

Bernd Wegener

TITLE
Chairman of Management Board and Chief Executive Officer
AGE
71

Andreas Bergmann

TITLE
Chief Scientific Officer & Member of Management Board
AGE
57

Frauke Hein

TITLE
Chief Business Officer & Head of Business Development

Joachim Struck

TITLE
Head of Research & Development

Jens Zimmermann

TITLE
Chief Medical Officer
TENURE
0.6 yrs
Board of Directors

Renke Lührs

TITLE
Chairman of Supervisory Board
AGE
58

Ute Kilger

TITLE
Vice Chairman of Supervisory Board
AGE
52
TENURE
1.3 yrs

Siegmund Karasch

TITLE
Member of Supervisory Board
AGE
53
TENURE
1.3 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
X
Management checks
We assess Deutsche Biotech Innovativ's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Deutsche Biotech Innovativ has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

VUA News

Simply Wall St News

VUA Company Info

Description

Deutsche Biotech Innovativ AG operates as a biotechnology company in Germany. The company develops Adrecizumab, a monoclonal adrenomedullin-specific antibody, which is in Phase II clinical trial as a therapy against septic shock to reduce sepsis mortality. It also develops various drugs for the prevention of breast cancer and tumor. The company was formerly known as Venetus Beteiligungen AG and changed its name to Deutsche Biotech Innovativ AG in August 2014. Deutsche Biotech Innovativ AG is based in Hennigsdorf, Germany.

Details
Name: Deutsche Biotech Innovativ AG
VUA
Exchange: DB
Founded:
€64,416,128
947,296
Website: http://www.dbi-ag.de
Address: Deutsche Biotech Innovativ AG
Neuendorfstrasse 15a,
Hennigsdorf,
Brandenburg, 16761,
Germany
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
DUSE VUA Share Capital Dusseldorf Stock Exchange DE EUR 27. May 2010
DB VUA Share Capital Deutsche Boerse AG DE EUR 27. May 2010
Number of employees
Current staff
Staff numbers
4
Deutsche Biotech Innovativ employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/21 21:18
End of day share price update: 2019/04/03 00:00
Last earnings filing: 2018/09/21
Last earnings reported: 2018/06/30
Last annual earnings reported: 2017/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.